Please login to the form below

IQWiG

This page shows the latest IQWiG news and features for those working in and with pharma, biotech and healthcare.

IQWiG) concluded it had not been proven to be superior to generic hydrocortisone.

Transforming access in rare diseases

From IQWiG in Germany to the HAS in France and the Pharmaceutical Benefits Advisory Committee in Australia, the reality we face is that all technology assessment organisations work in slightly different
Focus on value: A prescription for pharma

The pricing debate demands a common language to be developed
NICE backs use of AZ's Brilique as maintenance therapy

A similar verdict was reached by NICE's German counterpart IQWiG earlier this year.
Germany's IQWIG 'perplexed' by EMA's adaptive pathways plan

Reliance on real-world evidence questioned. German health technology assessment body IQWiG has said it is concerned by the reliance on real-world evidence in the EMA's plans for adaptive ... In a statement, IQWiG says that the EMA's recent report on its
IQWiG unimpressed with Cosentyx in two new indications

IQWiG had agreed last year that the combination had considerable added benefit in women but could not quantify the effect in men. ... Finally, IQWiG's review of the combination of Roche's melanoma therapy Cotellic (cobimetinib) with Zelboraf compared to

More from news
Approximately 23 fully matching, plus 43 partially matching documents found.

The gold standard of scientific evidence

PBAC appraisals, 64% of NICE appraisals and all IQWiG appraisals relied on RCT-based evidence.
Digital disruption

best patient outcomes - information that would probably come in very handy for submissions to the likes of NICE or IQWiG.
Stepping up to payer-driven market access

Combined with the demanding - and often less familiar - requirements of the GBA and IQWIG in Germany and other agencies in Europe, these changes make early understanding of the payer environment critical
The price is right?

IQWiG evaluations often focus on different patient populations from those used in the clinical trials. ... The dynamic between the G-BA and IQWiG makes pricing and reimbursement an extremely complex process.”.
Biosimilars - the same, but different?

After regulatory clarity, the focus will certainly move to health technology assessment bodies, such as Germany's IQWiG and the UK's NICE, if biosimilars' place in clinical practice is to ... For its part IQWiG has yet to assess any biosimilar products.

More from intelligence
Approximately 4 fully matching, plus 17 partially matching documents found.

Oncology drugs under AMNOG

Usually the G-BA also seeks the advice of expert Health Technology Assessment (HTA) body IQWiG (the Institute for Quality and Efficiency in Healthcare), to determine the level of added benefit ... The G-BA and IQWiG restricted these options to therapies

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.